Should SPL systems be placed in the upper or lower eyelid?

A prospective, randomised study into complications and outcomes of upper and lower eyelid subpalpebral lavage treatment systems in 66 equine eyes (2015-2023)



Annabelle Graham, Harry Carslake, Fernando Malalana



Introduction

- Subpalpebral lavage systems (SPL) are placed in upper or lower eyelids.
- There is weak evidence to recommend either location.
- Currently, site is based on:
 - clinician preference
 - location of the ocular lesion
 - degree of eyelid inflammation

One retrospective study has compared complication rates using a MILA SPL kit in upper vs lower lid and there was no significant difference.

Aims

The first prospective, randomised treatment trial to:

- describe and compare complications associated with SPLs in hospitalised horses between upper and lower eyelids.

Hypothesis: the upper eyelid SPL would <u>not</u> have a greater incidence of complications compared to lower lid.

Materials and methods

Data collected February 2015 - March 2023.

- Recruited if ocular pathology did not determine SPL location.
- SPL location was determined by a coin toss.
- MILA commercial kit used for all SPLs
- Placed in a routine manner by a boarded specialist, resident or intern.
- All secured using tape butterfly stents.
- SPLs assessed at every drug administration & by MRCVS daily.
- Data collected included: age, breed, sex, reason for treatment, duration of SPL placement, medication used.

Complications recorded


Major complications (required early removal of SPL)	Minor complications
Displacement of footplate from the fornix	Eyelid swelling
	Subcutaneous swelling/infection
	Loss of suture
Loss of footplate	Loss of injection port
Eyelid infection / abscess formation	Leakage / tube rupture

Results

65 horses with 66 SPLs. Mean age 12.1yrs (range 7m to 24yrs); mix of breeds.

- SPL in 36/66 upper eyelids, and 30/66 lower eyelids.
- SPL placed by interns 14/66; residents 44/66; and 8/66 specialists.
- Median duration SPL in place 10 days.

 Indication for SPL placement




* Confirmed or suspected

59 complications recorded in 38/66 eyes:

- Upper lid 32/59 (54.2%)
- Lower lid 27/59 (45.8%)

SQ abscess (n=2) o

Major complications 10/66 eyes (15.2%)



■ location upper ■ location lower

Results, continued

Most commonly 3 medications were given via SPL.

- Chloramphenicol (44/66; 66.7%)
- EDTA (29/66; 43.9%)
- Atropine (27/66; 40.9%)

Univariable analysis identified the following variables with P<0.25:

- Duration of placement
- Operator: intern
- Sex: mares
- Breed: WB/WBx
- Right eye
- Lower lid

However, of the above variables, no significant variables were identified on multivariable logistic regression models.

Limitations

Small sample size. Pre-study power calculations based on other studies = 110 horses needed (for 80% power, alpha 0.05, beta 0.2). Given the higher complication rate than previously reported, post-hoc power calculations estimated 762 cases would be needed for 80% power (alpha 0.05, beta 0.2).

Conclusions

Complications were recorded more frequently than previously reported (due to prospective study design). There was no statistically significant difference in complications between upper and lower locations.

Although the upper eyelid is not significantly more likely to see complications, upper lid complications more often required early SPL removal in the upper lid.

Institutional ethical approval was obtained. The authors had no conflicts of interest.